πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 131 of 173

  1. US 7582442

    Methods and compositions for using aleveolar macrophage phospholipase A2

    Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7582623

    Photoactive metal nitrosyls for blood pressure regulation and cancer therapy

    Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7582281

    Ethylenedicysteine (EC)-drug conjugates compositions and methods for tissue specific disease imaging

    Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7582279

    Blood-pool carrier for lipophilic imaging agents

    Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7582425

    Atlastin

    Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7582736

    Prostate cancer specific internalizing human antibodies

    Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7579173

    Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using the same

    Expires Mon Aug 20 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7579188

    Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

    Expires Mon Aug 20 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7579319

    Methods for improving the structure and function of arterioles

    Expires Mon Aug 20 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7579014

    Mesoporous compositions for use in drug delivery

    Expires Mon Aug 20 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7576175

    Alpha-4 beta-1 integrin ligands for imaging and therapy

    Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7575904

    Polymer grafting by polysaccharide synthases

    Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7576194

    UspA2 nucleic acid of moraxella catarrhalis

    Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7575873

    Reagents for diagnosing, imaging and treating atherosclerotic disease

    Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7572448

    Combined cancer treatment methods using selected antibodies to aminophospholipids

    Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7572788

    Compositions and methods relating to novel compounds and targets thereof

    Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7572442

    Selected antibody compositions for binding to aminophospholipids

    Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7572891

    Kidney-specific tumor vaccine directed against kidney tumor antigen G-250

    Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7569386

    Chondroitin synthase gene and methods of making and using same

    Expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7569542

    Anti-microbial targeting chimeric pharmaceutical

    Expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7569683

    UspA2 nucleic acid of Moraxella catarrhalis

    Expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7566447

    Biocides

    Expires Mon Jul 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7563457

    Nanoparticle assembled hollow spheres

    Expires Mon Jul 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7563874

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    Expires Mon Jul 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7563446

    Methods and compositions for inducing autoimmunity in the treatment of cancers

    Expires Mon Jul 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7560436

    Methods of treating gastrointestinal inflammation

    Expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7560229

    Methods of use of the enzymes of mycothiol synthesis

    Expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7560265

    Compositions for regulation of tumor necrosis factor-alpha

    Expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7560437

    Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase

    Expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7557138

    5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel

    Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7556927

    Methods for diagnosing, imaging and treating atherosclerotic disease

    Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7556942

    Tumor suppressor designated Hippo

    Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7557251

    Production of gossypol co-crystals

    Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7557194

    Antibody materials for an IBD-associated polypeptide

    Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7557096

    Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof

    Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7553484

    Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule

    Expires Mon Jun 25 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7553934

    Modified vitamin K-dependent polypeptides

    Expires Mon Jun 25 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7553935

    Modified vitamin K-dependent polypeptides

    Expires Mon Jun 25 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7550141

    Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids

    Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7550617

    Compositions and methods for the treatment of renal and cardiovascular disease

    Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7550005

    Coated implantable medical device

    Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7550503

    Physiologically active substances

    Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7547546

    Progenitor cells from wharton's jelly of human umbilical cord

    Expires Mon Jun 11 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7547759

    Induction of tumor immunity by variants of folate binding protein

    Expires Mon Jun 11 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7547686

    Combretastatin A-3 prodrug

    Expires Mon Jun 11 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7544670

    HoxD3, HoxA3 and HoxB3 compositions and methods for improved wound healing

    Expires Mon Jun 04 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7544358

    Treatment of acute lung injury, fibrosis and metastasis with antagonists of Ξ±vΞ²6

    Expires Mon Jun 04 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7544481

    Nucleic acids encoding CD40 binding protein

    Expires Mon Jun 04 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.